Generated by AI
Purple Biotech Ltd. ADR is a clinical-stage biotechnology company focused on developing first-in-class therapies for cancer. Its current pipeline centers on treatments designed to overcome tumor immune evasion and drug resistance, two major barriers that can limit the effectiveness of oncology care. The company’s programs include antibody-based immunotherapies and small-molecule candidates aimed at the tumor microenvironment, with research directed toward solid tumors and treatment-resistant cancers. Purple Biotech works at the intersection of immuno-oncology and precision drug development, seeking to address complex mechanisms that help cancer cells survive and evade treatment. Headquartered in Rehovot, Israel, Purple Biotech Ltd. ADR is positioned as a specialized cancer-focused developer within the broader biotechnology market.
Website4 Oppenheimer Street
Rehovot, 7670104
Israel
The latest articles about PPBT.
IM1240 tri-specific antibody (capped-CD3x5T4xNKG2A): Investigational New Drug (IND) application submission planned during 2027, followed by a first-in-human study IM1240 data to be presented in a plenary oral session at the 38th EORTC-NCI-AACR Symposium on November 20, 2026 REHOVOT, Israel, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize
Detailed price information for Purple Biotech Ltd ADR (PPBT-Q) from The Globe and Mail including charting and trades.
Summary of Nov 17's posts. Generated by AI.
Summary of Sep 3's posts. Generated by AI.
Summary of Sep 3's posts. Generated by AI.
Investors talking about PPBT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.